Latest News and Press Releases
Want to stay updated on the latest news?
-
Entrada Therapeutics announces that it has received authorization in the European Union to initiate its ELEVATE-45-201 clinical study.
-
New York, May 19, 2025 (GLOBE NEWSWIRE) -- This summer, shoppers across the U.S. have the chance to make an extraordinary difference in the lives of kids and young adults living with neuromuscular...
-
Entrada Therapeutics, Inc. (Nasdaq: TRDA) reports financial results for the first quarter ended March 31, 2025, and highlights recent business updates.
-
New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVYTM (nipocalimab-aahu) for the treatment of...
-
New York, April 08, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) and the International Association of Fire Fighters (IAFF) are celebrating over 70 years of partnership by launching...
-
CHARLOTTE, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) has teamed up with Burn Boot Camp, a leading boutique fitness franchise, for the 9th annual national 'Be...
-
New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of...
-
New York, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that Robert Califf, MD, MAAC, former Commissioner of the U.S. Food and Drug Administration and...
-
New York, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today launched the nation’s largest St. Patrick’s Day fundraising campaign, MDA Shamrocks, as part of its...
-
New York, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today celebrates the decision by the US Food and Drug Administration (FDA) to grant approval of a risdiplam...